{"id":"framycetin","rwe":[],"tags":[{"label":"framycetin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Transient receptor potential cation channel subfamily V member 1","category":"target"},{"label":"TRPV1","category":"gene"},{"label":"LRAT","category":"gene"},{"label":"MEN1","category":"gene"},{"label":"D09AA01","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"neomycin b","offLabel":[],"synonyms":["Neomycin B sulfate","Neomycin B","framycetin"],"timeline":[],"approvals":[],"brandName":"Neomycin B","ecosystem":[],"mechanism":{"target":"Lecithin retinol acyltransferase, Menin, Transient receptor potential cation channel subfamily V member 1","targets":[{"gene":"TRPV1","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily V member 1","protein":"Transient receptor potential cation channel subfamily V member 1"},{"gene":"LRAT","source":"DrugCentral","target":"Lecithin retinol acyltransferase","protein":"Lecithin retinol acyltransferase"},{"gene":"MEN1","source":"DrugCentral","target":"Menin","protein":"Menin"}],"modality":"Small Molecule","drugClass":"framycetin","explanation":"Imagine your cells have special channels that help control the flow of important molecules. Neomycin B blocks these channels, which can help reduce inflammation and other symptoms. This can be beneficial for people with certain conditions, but it's essential to understand how it works and its potential effects on the body.","oneSentence":"Neomycin B works by blocking the transient receptor potential cation channel subfamily V member 1, which is involved in various cellular processes.","technicalDetail":"Neomycin B binds to the transient receptor potential cation channel subfamily V member 1, inhibiting its activity and modulating the flow of calcium ions into the cell, which can lead to anti-inflammatory and other effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1896","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FRAMYCETIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FRAMYCETIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:37:21.804646","biosimilars":[],"competitors":[{"drugName":"nitrofurazone","drugSlug":"nitrofurazone","fdaApproval":"1945-10-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"benzalkonium","drugSlug":"benzalkonium","fdaApproval":"","relationship":"same-class"},{"drugName":"triclosan","drugSlug":"triclosan","fdaApproval":"1997-07-11","relationship":"same-class"},{"drugName":"cetylpyridinium","drugSlug":"cetylpyridinium","fdaApproval":"","relationship":"same-class"},{"drugName":"aluminium chlorohydrate","drugSlug":"aluminium-chlorohydrate","fdaApproval":"","relationship":"same-class"},{"drugName":"povidone-iodine","drugSlug":"povidone-iodine","fdaApproval":"1985-11-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"clioquinol","drugSlug":"clioquinol","fdaApproval":"","relationship":"same-class"},{"drugName":"chlorhexidine","drugSlug":"chlorhexidine","fdaApproval":"1976-09-17","patentExpiry":"Oct 2, 2027","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"framycetin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nitrofurazone","brandName":"nitrofurazone","genericName":"nitrofurazone","approvalYear":"1945","relationship":"same-class"},{"drugId":"benzalkonium","brandName":"benzalkonium","genericName":"benzalkonium","approvalYear":"","relationship":"same-class"},{"drugId":"triclosan","brandName":"triclosan","genericName":"triclosan","approvalYear":"1997","relationship":"same-class"},{"drugId":"cetylpyridinium","brandName":"cetylpyridinium","genericName":"cetylpyridinium","approvalYear":"","relationship":"same-class"},{"drugId":"aluminium-chlorohydrate","brandName":"aluminium chlorohydrate","genericName":"aluminium chlorohydrate","approvalYear":"","relationship":"same-class"},{"drugId":"povidone-iodine","brandName":"povidone-iodine","genericName":"povidone-iodine","approvalYear":"1985","relationship":"same-class"},{"drugId":"clioquinol","brandName":"clioquinol","genericName":"clioquinol","approvalYear":"","relationship":"same-class"},{"drugId":"chlorhexidine","brandName":"chlorhexidine","genericName":"chlorhexidine","approvalYear":"1976","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03717025","phase":"NA","title":"Comparison of Surgical Methods on Resistant Sites in Stable Vitiligo Patients","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2017-07-01","conditions":["Vitiligo"],"enrollment":20,"completionDate":"2018-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"003514","UNII":"4BOC774388","CHEBI":"CHEBI:7508","INN_ID":"253","RXNORM":"235749","UMLSCUI":"C0016673","ChEMBL_ID":"CHEMBL184618","KEGG_DRUG":"D05140","DRUGBANK_ID":"DB00452","PDB_CHEM_ID":"NMY","PUBCHEM_CID":"8378","SNOMEDCT_US":"373765007","MESH_DESCRIPTOR_UI":"D005601"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":200,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"D09AA01","allCodes":["D09AA01","R01AX08","S01AA07"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neomycin B is a small molecule antibiotic with various clinical applications, including the treatment of conditions such as poliomyelitis, vaginitis, hordeolum, osteomyelitis, and cataract. It is used in experimental vaccines, including the Sabin Inactivated Poliovirus Vaccine, and has been studied for its safety and immunogenicity in adults, children, and infants.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}